

Time Table

Day 1, March 6 (Thu)

Explanatory Notes	AJS = ASCO/JSMO Joint Symposium	JS = Joint Symposium	ME = Meet the Experts	O = Oral Session	PAP = Patient Advocate Program	E = English Session
SS = Special Session	APJS = Asian Pacific Society Symposium	PSY = Presidential Symposium	MeS = Medical Seminar	MO = Mini Oral Session	L = Live Streaming	ES = Evening Seminar
SP = Special Lecture	EJS = ESMO/JSMO Joint Symposium	SY = Symposium	ES = Evening Seminar	P = Poster Session	OD = On-demand Distribution	PS = Presidential Session
PS = Presidential Session	SJS = SIOG/JSMO Joint Symposium	CP = Committee Program	MoS = Morning Seminar	HoD = Highlight of the Day	SI = Simultaneous Interpretation (E&J)	

		7	8	9	10	11	12	13	14	15	16	17	18	19			
Kobe Portopia Hotel, South Wing	Room 1 Portopia Hall 1F			PS1 Lung Cancer / Thoracic Cancer, Hematologic Malignancies P.115	ELIO 8:30-11:10				SP1 Near infrared photodynamic therapy (NIR-PIT) of cancer P.115	LO 14:00-15:00		PSY1 Clinical application of whole genome sequencing P.116					
	Room 2 Ohwada A 1F			SY1 New multimodal treatment strategy for GI cancer P.117	EO 8:30-10:00	SY2 Current Status and Prospects of Treatment Strategies for Thyroid Cancer P.117	EO 10:10-11:40	MeS1 Cancer Genomic Medicine guided by CGP testing P.85	12:00-12:50	PSY2 How to use uninsured medicines recommended by genomic medicine? P.118	LO 14:00-15:30	HoD1 Highlight of the Day 1 P.119	ES1 Treatment Strategies for ALK-Positive Lung Cancer P.96				
	Room 3 Ohwada B 1F			JS1 JCA/JSCO/JSMO initiatives for precision oncology P.120	E 8:30-10:30	SS Importance and Reality of Oncocardiology based on Komuro Group Study P.121	EO 10:10-11:40	MeS2 Beyond the knife: Towards the Era of Tumor-agnostic MRD Testing P.85	12:00-12:50	O1 Hematologic Malignancies P.121	E 14:00-15:20	JS2 Timing of consulting cardiologists in cancer treatment and subsequent follow-up P.122	ES2 Thyroid Cancer Update in South Korea and Japan P.96				
	Room 4 Ohwada C 1F			SY3 Cutting edge of genomic medicine and novel therapy in hematologic malignancies P.123	EO 8:30-10:00			MeS3 Patients-centered treatment for EGFR mutation-positive lung cancer P.86	12:00-12:50	JS3 Next generation Precision oncology and genetic medicine P.123	14:00-16:00	O2 Gastrointestinal Cancer 1 P.124	ES3 The Latest Treatment Strategy in Lung Cancer ~ Diagnosis and Therapy for Patient's Life ~ P.97				
	Room 5 Topaz B1F			SY4 Tumor board for patients with bone metastasis - management of a conference that maximize multidisciplinary expertise- P.125	EO 8:30-10:00		O3 Multidisciplinary Team Program P.126	10:10-11:30	MeS4 The role of biomarkers in gastric and colon cancer treatment and future prospects P.86	12:00-12:50	SY5 Next-generation regimen management through multi-disciplinary collaboration P.126	LO 14:00-15:30	MO1 Palliative Care / Symptom Management 1 (Psycho-Oncology) P.127	MO2 Palliative Care / Symptom Management 2 (Palliative Medicine) P.128	ES4 Latest Clinical Evidence & Future Outlook in NSCLC treatment P.97		
	Room 6 Emerald B1F							MeS5 Present and future perspective on clinical practice for hereditary cancers. The insights from SCOA/Japan MONSTAR SCREEN initiative. P.86	12:00-12:50	O4 Gynecologic Cancer P.130	E 14:00-15:20	MO3 Gynecologic Cancer 1 P.130	E 16:10-17:10	MO4 Gynecologic Cancer 2 P.131	ES5 Shifting the Focus: Financial and Time Toxicity in Cancer Care P.97		
Kobe International Conference Center	Room 7 Main Hall B1F /1F			SY6 New drug treatments for gynecological cancers P.132	EO 8:30-10:00	PSY2 Open discussion for the revision of conditional approval system from Ministry of Health, Labour and Welfare in 2024 P.132	EO 10:10-11:40	MeS6 Fruquintinib: Redefining Late-line Options for Colorectal Cancer P.86	12:00-12:50	SJS Lessons to Learn from the Leading Nations in Geriatric Oncology P.133	LO 14:00-15:30	AJS Drugging the Undruggable Targets P.133	ES6 Treatment strategies for non-small cell lung cancer from clinical and statistical interpretations P.98				
	Room 8 International Conference Room 3F			SY7 How do we select the partner for the combination immunotherapy? P.135	EO 8:30-10:00	O5 Translational Research / Clinical Pharmacology P.136	EO 10:10-11:30	MeS7 Leading-edge treatment strategies for HER2 negative advanced gastric cancer P.87	12:00-12:50	SY8 Challenges for implementation of translational research in clinical trials P.136	LO 14:00-15:30	O6 Clinical Trial Facilitation Program P.137	ES7 Treatment strategy for esophageal cancer in 1st line setting for long survival P.137				
	Room 9 401 + 402 4F			MO5 Gastrointestinal Cancer 1 (Gastric Cancer 1 Basic) P.139	E 8:30-9:30	MO6 Gastrointestinal Cancer 2 (Gastric Cancer 2 Trial) P.140	E 9:30-10:30	MO7 Gastrointestinal Cancer 3 (Gastric Cancer 3 Surgical Department) P.141	E 10:30-11:30	MeS8 Optimal Treatment for MSI-H Colorectal Cancer P.87	12:00-12:50	O7 Lung Cancer / Thoracic Cancer 1 P.142	E 14:00-15:30	MO8 Lung Cancer / Thoracic Cancer 1 (Small Cell Lung Cancer 1) P.143	E 16:30-17:40	MO9 Lung Cancer / Thoracic Cancer 2 (Small Cell Lung Cancer 2) P.144	ES8 Perspectives of new treatment strategies in soft tissue sarcoma P.98
	Room 10 501 5F			O8 Cross-sectional Program P.145	E 8:30-9:50	O9 Cross-sectional Program 1 P.146	E 10:00-11:00	MeS9 Implementation of Immunotherapy in Biliary Tract Cancer P.87	12:00-12:50	MO10 Hepatobiliary / Pancreatic Cancer 1 (Pancreatic Cancer 1) P.147	E 14:00-15:00	MO11 Hepatobiliary / Pancreatic Cancer 2 (Pancreatic Cancer 2) P.148	E 15:00-16:00	MO12 Hepatobiliary / Pancreatic Cancer 3 (Pancreatic Cancer 3) P.149	ES9 Cutting edge of Hepatocellular Carcinoma Treatment: Treatment Strategies based on Clinical trials and Real World Data P.99		
	Room 11 502 5F			MO13 Head and Neck Cancer 1 (Head and Neck Cancer 1, Thyroid Cancer, Salivary Gland Cancer) P.150	E 8:30-9:30			MeS10 TREATMENT LANDSCAPE IN CERVICAL CANCER: CURRENT STATUS AND FUTURE DIRECTIONS P.87	12:00-12:50	MO14 Head and Neck Cancer 2 (Head and Neck Cancer 2) P.151	E 14:00-15:00			O10 Head and Neck Cancer P.152	ES10 Personalized therapy for colorectal cancer ~ Chemotherapy and supportive care for individual patients ~ P.99		
	Room 12 504 + 505 5F			PS1 Presidential Session live streaming 8:30-11:10				MeS11 Revolutionizing Gynecologic Cancer Treatment: Current Landscape and Future Horizons P.88	12:00-12:50						ES11 Towards high-quality cancer patient support: perspectives on disease understanding and treatment decisions from both patients and healthcare professionals P.100		
Kobe International Exhibition Hall	Room 13 2A Meeting Room 2F			MO15 Patient Advocacy / Survivorship 1 (Treatment) P.153	E 8:30-9:30	MO16 Patient Advocacy / Survivorship 2 (Social Context Surrounding Patients) P.154	E 9:30-10:30	MO17 Brain Tumor P.155	E 10:30-11:20	MeS12 Combination strategies for the treatment of advanced and recurrent endometrial cancer P.88	12:00-12:50	MO18 Breast Cancer 1 (Perioperative 1) P.155	E 14:00-14:50	MO19 Breast Cancer 2 (Perioperative 2) P.156	E 16:10-17:10	MO20 Breast Cancer 3 (Others) P.157	ES12 The new wave of ADC in metastatic Triple Negative Breast Cancer P.100
	Room 14 3A Meeting Room 3F			CP1 禁煙推進セッション / SNS ワーキンググループシンポジウム、オンコロジー領域における SNS 利用 P.158	8:30-10:00	CP2 Educational activities on Medical Oncology in Asia-Pacific region P.158	EO 10:10-11:40	MeS13 New biomarker based treatment strategies for metastatic gastric cancer P.88	12:00-12:50	CP3 Generative AI will brighten the future of medical oncology! P.159	14:00-15:30	CP4 How do we communicate the appeal of Medical Oncology? [JSMO University] P.160	16:00-17:30	ES13 ICI Treatment strategies in Advanced Lung Cancer for diverse groups of patients P.100			
Kobe Portopia Hotel, South Wing	Meet the Experts ① Rose / Iris B1F						ME1 Perioperative Pembrolizumab + Chemotherapy for Gastric and Gastroesophageal Junction Cancer P.161	EO 10:40-11:40			ME2 Developing a Career in Clinical Trials P.161	EO 14:00-15:00	ME3 Spatial transcriptome analysis on tumor microenvironment P.161	16:00-17:00			
	Meet the Experts ② Cattleya / Lilac B1F						ME4 Pharmacotherapy and supportive care for aging head and neck cancer patients P.162	EO 8:30-9:30	ME5 The pancreatic genomic landscape: biology, test strategies and precision medicine guidance P.162	EO 10:40-11:40	ME6 Precision Therapy in Gastric Cancer P.162	EO 14:00-15:00	ME7 Challenges in diagnosis and treatment of rare T-cell lymphomas P.162	EO 16:00-17:00			
Kobe International Exhibition Hall	PAP Room Exhibition Hall B 2F			PAP PAP Special Lecture ① 8:40-9:55 PAP Orientation ①	EO 9:00-9:45	PAP PAP Basic Lecture ① EO 10:00-10:45	PAP PAP Special Lecture ② EO 11:00-11:45	PAP PAP Luncheon Seminar EO 12:00-12:45	PAP PAP Basic Lecture ② EO 14:00-14:45	PAP PAP Basic Lecture ③ EO 15:00-15:45	PAP PAP Special Lecture ③ EO 16:00-16:45						
	Poster Room Convention Hall / Exhibition Hall No.2 / No.3 / 1F			Putting Up Posters 8:00-9:00		Posters Display	9:00-13:05	Posters Display	9:00-13:05	Poster Session P.163	13:05-13:50	Posters Display	13:50-17:10	Posters Removal	17:10-17:40		

Time Table

Day 2, March 7 (Fri)

Explanatory Notes	AJS = ASCO/JSMO Joint Symposium	JS = Joint Symposium	ME = Meet the Experts	O = Oral Session	PAP = Patient Advocate Program	E = English Session
SS = Special Session	APJS = Asian Pacific Society Symposium	PSY = Presidential Symposium	MeS = Medical Seminar	MO = Mini Oral Session	L = Live Streaming	ES = Evening Session
SP = Special Lecture	EJS = ESMO/JSMO Joint Symposium	SY = Symposium	ES = Evening Seminar	P = Poster Session	OD = On-demand Distribution	ES = English Session
PS = Presidential Session	SJS = SIOG/JSMO Joint Symposium	CP = Committee Program	MoS = Morning Seminar	HoD = Highlight of the Day	SI = Simultaneous Interpretation (E&J)	

		7	8	9	10	11	12	13	14	15	16	17	18	19	
Kobe Portopia Hotel, South Wing	Room 1 Portopia Hall 1F			PSY4 ctDNA-guided cancer therapy P.203		SP2 The Era of Liquid Biopsy Biomarkers and Precision Medicine in Gastrointestinal Cancers P.203		General Assembly 12:45-13:35	Award Ceremony 13:35-14:05	Award Lecture 14:05-14:25		PS2 Genitourinary Cancer, Head and Neck Cancer, Translational Research / Clinical Pharmacology P.204			
	Room 2 Ohwada A 1F	MoS1 Evolution of Colorectal Cancer Treatment and Use of Biomarkers: Realigning Personalized Medicine Based on DNA Methylation Status P.105	PS3 Gastrointestinal Cancer P.205			MeS14 Treatment strategy up to date for HER2 negative Gastric Cancer P.88						HoD2 Highlight of the Day 2 P.206	ES14 How should cost-effectiveness be considered when selecting antiemetic therapy? P.101		
	Room 3 Ohwada B 1F		SY9 Perioperative treatment for resectable/Borderline resectable pancreatic cancer P.207	SY10 Is GC plus immune checkpoint inhibitor or GC plus S-1 the first-line systemic therapy for unresectable biliary tract cancer? P.207							JS4 Recent Advances and Future Perspectives of Cellular Immunotherapy -CAR T-cell and T-cell engager- P.208		ES15 To seek... Not to seek... 21 - Meeting the needs of cancer treatment using Join ~ P.101		
	Room 4 Ohwada C 1F	MoS2 New treatment strategy for Mantle Cell Lymphoma P.105	JS5 Clinical practice of Geriatric Oncology P.210			MeS15 Update on Trastuzumab Derivatant for the Management of HER2-Expressing Metastatic Breast Cancer P.89					SY11 New treatment strategy for NSCLC with oncogenic driver mutation P.210	MO21 Lung Cancer / Thoracic Cancer 3 (Lung Cancer / Thoracic Cancer, Artificial Intelligence) P.211		ES16 Delivering the benefits of immune combination therapy to patients P.102	
	Room 5 Topaz B1F	MoS3 Understanding the data of HR-positive HER2-negative advanced recurrent breast cancer - clinical and statistical aspects - P.105	SY12 Conflicts in Clinical Oncology Practice P.212	SY13 Improvement of cancer pain relief and building of a collaborative system P.213		MeS16 New standard of care for unresectable biliary tract cancer: Combination chemo-immunotherapy based on phase III trial data P.89					MO22 Multidisciplinary Team Program 1 P.213	MO23 Multidisciplinary Team Program 2 P.214	MO24 Multidisciplinary Team Program 3 P.215	ES17 Updating treatment strategy in ALK-positive NSCLC - 5 year follow up from the CROWN study - P.102	
	Room 6 Emerald B1F	MoS4 Utilization of liquid CGP for mCRC P.106	MO25 Rare Cancer / Cancer of Unknown Primary 1 (Rare Cancer 1) P.216	MO26 Rare Cancer / Cancer of Unknown Primary 2 (Rare Cancer 2) P.217		MeS17 Systemic therapy for Advanced Thyroid Cancer: Recent Advances and Challenges P.89								ES18 Multidisciplinary Care in Cancer Cachexia P.102	
Kobe International Conference Center	Room 7 Main Hall B1F /1F	MoS5 Evolving Treatment of Cervical Cancer: Advances at the Forefront and the Role of Multidisciplinary Collaboration P.106	SY14 How to use ADCs in metastatic /recurrent breast P.218		EJS Economic Issues in Cancer Care P.218		MeS18 How should we treat patients with EGFR mutation? P.89				APJS Education for Oncologists P.219		ES19 An opportunity to be informed about head and neck cancer treatment P.103		
	Room 8 International Conference Room 3F	MoS6 A Dialogue Between Medical Oncologists and Surgeons - The Current Status and Future of Gastric Cancer Treatment P.106	SY15 Companion diagnosis required for pathology P.220		MO27 Translational Research / Clinical Pharmacology 1 P.220		MeS19 Recent Advances in the Management of Triple-Negative Breast Cancer P.90				SY16 Advances and Challenges in development of Novel Therapies Based on TR Research P.221	MO28 Clinical Trial Facilitation Program 1 P.222			
	Room 9 401 + 402 4F	MoS7 First-line drug therapy for esophageal cancer: What is the optimal treatment option for long-term survival? P.107	MO29 Hematologic Malignancies 1 P.224	MO30 Hematologic Malignancies 2 P.224		MeS20 Treatment Strategies for EGFR Mutation-Positive Lung Cancer - Aiming for Optimal Patient Care P.90					JS6 Issues and problems with bone metastasis cancer boards P.225		ES20 Establishing Medical and Multidisciplinary Collaboration to Support People Living with and beyond Cancer P.103		
	Room 10 501 5F	MoS8 Transforming Lives: Towards Excellence in Cancer Outcomes P.107	O11 Genitourinary Cancer (Renal cancer / Prostate Cancer) P.227	MO31 Genitourinary Cancer 1 (Renal Cancer -Systemic Therapy-) P.227		MeS21 HER2DX: Redefining Treatment Strategies in HER2-Positive Breast Cancer P.90					MO32 Hepatobiliary / Pancreatic Cancer 3 (Biliary Tract Cancer) P.228	MO33 Hepatobiliary / Pancreatic Cancer 4 (Liver Cancer) P.229		ES21 Chemotherapy for colorectal cancer- practice and recent topics P.103	
	Room 11 502 5F	MoS9 Lung Cancer Genetic Testing: Navigating Lung Cancer Genetic Testing Options P.107	O12 Lung Cancer / Thoracic Cancer 2 P.230	MO34 Lung Cancer / Thoracic Cancer 4 (Other) P.231		MeS22 10-Base Perioperative Therapies in NSCLC: Evolving Our Mindsets as We Strive to Cure P.90					O13 Breast Cancer P.232	MO35 Breast Cancer 4 (Metastatic Breast Cancer) P.233		ES22 Revisiting the Treatment Strategies for Squamous Cell Lung Cancer - Positioning of Nectin4 - P.104	
	Room 12 504 + 505 5F	MoS10 Comparing Data among Different Trials: Network Meta Analysis and Matching Adjusted Indirect Comparison P.108	PS3 Presidential Session live streaming 8:20-11:00			MeS23 The Frontline of HER2-Targeted Therapy for Gastric Cancer P.91					PS2 Presidential Session live streaming 15:00-17:40		ES23 Precision Medicine in Colorectal Cancer ~Organizing and Practicing the Evidence~ P.104		
Kobe International Exhibition Hall	Room 13 2A Meeting Room 2F		SY17 Strategy for Patient-Public Involvement in Cancer Reserch P.234		O14 Patient Advocacy / Survivorship P.234		MeS24 New Treatment Strategies for Metastatic Urothelial Carcinoma P.91			SY18 Advances in antibody therapy as cancer treatment P.235	MO36 Cross-sectional Program 2 P.236				
	Room 14 3A Meeting Room 3F	MoS11 Considering Optimal Treatment for Elderly Lung Cancer Patients P.108		CP5 Future Career Development and Work Style Reform: Ideal and Reality P.237		MeS25 Targeting actionable mutations to overcome endocrine resistance with liquid biopsies P.91				CP6 City vs. country, cancer specialty hospital vs. general hospital: A real comparison of older cancer care! P.237		ES24 EGFR Exon 20 Insertion Mutation Therapy and Skin Disorder Management P.104			
Kobe Portopia Hotel, South Wing	Meet the Experts ① Rose / Iris B1F		ME8 Perioperative drug therapy: past, present, and near future P.239		ME9 Cancer Survivorship: Assisting the process of patients/ survivors' adjustment P.239										
	Meet the Experts ② Cattleya / Lilac B1F											ME10 Role of systemic therapy for hepatocellular carcinoma P.240	ME11 The Management of older cancer patients with cognitive impairment P.240		
Kobe International Exhibition Hall	PAP Room Exhibition Hall B 2F		PAP PAP Special Lecture ④ P.240	PAP PAP Basic Lecture ④ P.240	PAP PAP Basic Lecture ⑤ P.240	PAP PAP Luncheon Seminar ② P.240				PAP PAP Special Lecture ⑤ P.240	PAP PAP Special Lecture ⑥ P.240	PAP PAP Special Lecture ⑦ P.240			
	Poster Room Convention Hall / Exhibition Hall No.2 / No.3 / 1F		8:00-9:00 Putting Up Posters							9:00-14:05 Posters Display		14:05-14:50 Poster Session P.241	14:50-17:10 Posters Display	17:10-17:40 Posters Removal	

Time Table

Day 3, March 8 (Sat)

Explanatory Notes	AJS = ASCO/JSMO Joint Symposium	JS = Joint Symposium	ME = Meet the Experts	O = Oral Session	PAP = Patient Advocate Program	E = English Session
SS = Special Session	APJS = Asian Pacific Society Symposium	PSY = Presidential Symposium	MeS = Medical Seminar	MO = Mini Oral Session	L = Live Streaming	
SP = Special Lecture	EJS = ESMO/JSMO Joint Symposium	SY = Symposium	ES = Evening Seminar	P = Poster Session	O = On-demand Distribution	
PS = Presidential Session	SJS = SIOG/JSMO Joint Symposium	CP = Committee Program	MoS = Morning Seminar	HoD = Highlight of the Day	A = Simultaneous Interpretation (E&J)	

		7	8	9	10	11	12	13	14	15	16	17	18	19
Kobe Portopia Hotel, South Wing	Room 1 Portopia Hall 1F			PS4 Hepatobiliary / Pancreatic Cancer, Rare Cancer, Breast Cancer 8:30-11:10 P.277							HoD3 Highlight of the Day 3 15:00-16:30 P.278			
	Room 2 Ohwada A 1F	MoS12 7:30-8:20 The cutting edge of endoscopic treatment for pancreatic and biliary cancer - from the viewpoint of Onco-endoscopist - P.109	SY19 8:30-10:00 Not too little, not too much : Optimizing more vs. less treatment for older patients with breast cancer P.279	PSY5 10:10-11:40 Hereditary tumors in rare cancers P.279	MeS26 12:00-12:50 Advances in the treatment strategy of la/mUC P.91	PSY6 14:00-15:30 Cancer gene panel testing should be performed before the primary treatment? P.280								
	Room 3 Ohwada B 1F		O15 8:30-9:30 Gastrointestinal Cancer 2 P.281	SY20 10:10-11:40 New treatments on the horizon for the upper GI cancers P.281	MeS27 12:00-12:50 Advances in Personalized Medicine for Breast Cancer: Focusing on the MyChoice Diagnostic System P.92	SY21 14:00-16:30 Clinical application of AI to Cancer Research & Care P.282								
	Room 4 Ohwada C 1F	MoS13 7:30-8:20 Consider infectious disease prevention in cancer patients P.109	PSY7 8:30-10:00 New molecular-targeted therapy for colorectal cancers P.283	SY22 10:10-11:40 Development of new technologies for lung cancer P.283	MeS28 12:00-12:50 The significance and positioning of the COVID-19 vaccine for specialists involved in cancer treatment. P.92	SY23 14:00-15:30 Treatment strategy for mRCC 2025: Is HIF-2 α inhibitor a game changer? P.284								
	Room 5 Topaz B1F	MoS14 7:30-8:20 Drug Loss -Is it really drug loss? What should medical institutions do? P.109	SY24 8:30-10:00 Management of Chemotherapy-induced peripheral neuropathy P.285	O16 10:10-11:30 Palliative Care / Symptom Management P.286	MeS29 12:00-12:50 Tumor immunity and inhibition of angiogenesis P.93	SY25 14:00-15:30 Optimization of long-term health management of childhood and adolescent cancer survivorship: can we support their transition to adult care? P.287	MO37 15:30-16:30 Palliative Care / Symptom Management 3 (Symptom Management) P.288							
	Room 6 Emerald B1F	MoS15 7:30-8:20 New treatment strategy for hormone receptor positive HER2 negative breast cancer - low to use ADC in Clinical Practice - P.110	JS7 8:30-10:30 Radiation therapy for Oligometastasis P.289		MeS30 12:00-12:50 Latest Insights in Translational Research for Small Cell Lung Cancer Treatment Development P.93	MO38 14:00-15:00 Gastrointestinal Cancer 4 (Esophageal Cancer 1) P.289	MO39 15:10-16:10 Gastrointestinal Cancer 5 (Esophageal Cancer 2) P.290							
Kobe International Conference Center	Room 7 Main Hall B1F /1F	MoS16 7:30-8:20 Diagnosis and treatment of cancer of unknown primary P.110	SY26 8:30-10:00 "Focused"/"Spotlighted" Early Phase 1 Oncology Drug Development 2025 P.292	SY27 10:10-11:40 Current state and future direction of immunotherapies in malignant lymphoma and multiple myeloma P.292	MeS31 12:00-12:50 Global standard in HR(+) HER2(+) advanced recurrent breast cancer P.93	JS8 14:00-16:00 Using Digital Technology in Supportive and Palliative Care for Cancer P.293								
	Room 8 International Conference Room 3F	MoS17 7:30-8:20 Basics and clinical activity of ADC - Trastuzumab Deruxtecan - P.110	SY28 8:30-10:00 Current updates to learn about clinical trial modernization P.294	SY29 10:10-11:40 Rare cancers with promising drugs in the future P.294	MeS32 12:00-12:50 Advances in r/DBLCL Treatment and Unmet Medical Needs P.94	SY30 14:00-15:30 Future outlook on MRD testing in peri-operative clinical trials P.295	MO40 15:30-16:30 Clinical Trial Facilitation Program 2 P.296							
	Room 9 401 + 402 4F	MoS18 7:30-8:20 New paradigm for R/R Follicular Lymphoma ~ Bispecific antibody ~ P.110	MO41 8:30-9:30 Translational Research / Clinical Pharmacology 2 P.297	MO42 9:30-10:30 Translational Research / Clinical Pharmacology 3 (Basic Research) P.297	MO43 10:30-11:30 Translational Research / Clinical Pharmacology 4 (Molecular Diagnostics / Genomic Medicine / Companion Diagnostics) P.298	MeS33 12:00-12:50 Changes in AML treatment strategies-Focusing on FLT3 Inhibitors- P.94	MO44 14:00-15:00 Hematologic Malignancies 3 (Lymphoma 1) P.299	MO45 15:10-16:00 Hematologic Malignancies 4 (Lymphoma 2) P.300						
	Room 10 501 5F	MoS19 7:30-8:20 New Treatment for SCLC: Safety and Efficacy of IMDELLTRA P.111	MO46 8:50-9:40 Lung Cancer / Thoracic Cancer 5 (Non-Small Cell Lung Cancer 1 (Immunotherapy 1)) P.301	MO47 9:40-10:30 Lung Cancer / Thoracic Cancer 6 (Non-Small Cell Lung Cancer 2 (Immunotherapy 2)) P.302	MO48 10:40-11:40 Lung Cancer / Thoracic Cancer 7 (Non-Small Cell Lung Cancer 3 (Perioperative Treatment, Locally Advanced)) P.303	MeS34 12:00-12:50 Evolving treatment landscape for EGFR exon20 insertion NSCLC P.94	MO49 14:00-15:00 Lung Cancer / Thoracic Cancer 8 (Non-Small Cell Lung Cancer 4 (TKI 1)) P.304	MO50 15:10-16:20 Lung Cancer / Thoracic Cancer 9 (Non-Small Cell Lung Cancer 5 (TKI 2)) P.305						
	Room 11 502 5F	MoS20 7:30-8:20 Comprehensive genomic profiling test P.111	MO51 8:30-9:30 Genitourinary Cancer 2 (Prostate Cancer, Urothelial Cancer -Clinical-) P.306	MO52 9:40-10:40 Genitourinary Cancer 3 (Prostate Cancer, Urothelial Cancer, Basic Research, Other) P.307	MO53 10:40-11:40 Gastrointestinal Cancer 6 (Colorectal Cancer 1, Other Basic) P.307	MeS35 12:00-12:50 Advancing Precision Oncology: Caris's Innovative Technologies and Clinical Impact in Japan P.94	MO54 14:00-15:00 Gastrointestinal Cancer 7 (Colorectal Cancer 2, Trial) P.308	MO55 15:00-16:00 Gastrointestinal Cancer 8 (Colorectal Cancer 3, Other Retro) P.309						
	Room 12 504 + 505 5F	MoS21 7:30-8:20 Current status of CGP and introduction of new panel P.111	PS4 8:30-11:10 Presidential Session live streaming		MeS36 12:00-12:50 Key points of gastric cancer chemotherapy to keep in mind now ~ Evidence & Practice ~ P.95									
Kobe International Exhibition Hall	Room 13 2A Meeting Room 2F	MoS22 7:30-8:20 New treatment options for non-small cell lung cancer P.112	MO56 8:30-9:20 Rare Cancer / Cancer of Unknown Primary 3 (Sarcoma) P.311		MeS37 12:00-12:50 Treatment Strategy & Practice for Unresectable Pancreatic Cancer P.95					O17 14:00-15:50 Rare Cancer / Cancer of Unknown Primary P.312				
	Room 14 3A Meeting Room 3F	MoS23 7:30-8:20 Treatment Strategy for EGFRm+ Lung Cancer: Tailoring Treatment Approaches Based on Mutation Subtype P.112			MeS38 12:00-12:50 Optimal central venous device selection for chemotherapy P.95					MO57 14:00-15:00 Cross-sectional Program 3 P.313				
Kobe Portopia Hotel, South Wing	Meet the Experts ① Rose / Iris B1F		ME12 8:30-9:30 New Phase in Brain Tumor Treatment - Precision Therapy, Gene Therapy, International Collaboration P.314		ME13 10:30-11:30 Patient-Centered Care for adolescents and young adults with cancer P.314					ME14 14:00-15:00 Challenges with biomarker-based therapy development P.314				
	Meet the Experts ② Cattleya / Lilac B1F		ME15 8:30-9:30 State of the art, perspectives and challenges in NSCLC oncogene addiction P.315		ME16 10:30-11:30 Future of metastatic prostate cancer P.315					ME17 15:30-16:30 The career development of female oncologists in the United States P.315				
Kobe International Exhibition Hall	PAP Room Exhibition Hall B No.1 2F	PAP 8:00-8:15 PAP Orientation ①	PAP 8:30-9:20 PAP Applied Lecture ①	PAP 9:30-10:20 PAP Applied Lecture ②	PAP 10:30-11:20 PAP Applied Lecture ③		PAP 12:00-12:50 PAP Luncheon Seminar ③			PAP 14:00-16:10 PAP Applied Lecture ④				
	Poster Room Convention Hall / Exhibition Hall No.2 No.3 1F		8:00-9:00 Putting Up Posters		9:00-13:05 Posters Display			13:05-13:50 Poster Session P.316		13:50-14:20 Posters Removal				